Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol PAX5 contributors: mct - updated : 27-08-2015
HGNC name paired box 5
HGNC id 8619
EXPRESSION
Type
   expressed in (based on citations)
organ(s)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Lymphoid/Immunetonsils    
Reproductivemale systemtestis   
 male systemprostate   
Respiratorylung    
tissue
SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
Blood / Hematopoietic    
Lymphoid    
cells
SystemCellPubmedSpeciesStageRna symbol
Lymphoid/ImmuneB cell Homo sapiens
cell lineage
cell lines
fluid/secretion
at STAGE
physiological period fetal, pregnancy
Text developing central nervous system
PROTEIN
PHYSICAL PROPERTIES
STRUCTURE
motifs/domains
  • a paired DNA binding domain with a truncated homeo domain
  • two structurally distinct subdomains, N terminal (NTS) and C terminal subdomains
  • a truncated helix-turn helix (homeo) DNA binding domain
  • an intermediary octapeptide motif
  • a nuclear localization signal (NLS) in the central domain
  • HOMOLOGY
    interspecies homolog to C.elegans F14F3.1
    homolog to murine Pax5
    Homologene
    FAMILY
  • paired box family of transcription factor
  • CATEGORY transcription factor
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,nucleus
    basic FUNCTION
  • required for initiating B cell lineage and maintain,
  • neural development, spermatogenesis
  • playing an essential role for B-cell differentiation
  • involved in several chromosome translocations that fuse its N-terminal paired DNA-binding domain with the C-terminal regulatory sequences of ETV6, FOXP1, ZNF521 or ELN
  • not only crucial for B-cell lymphopoiesis but also for the development of B-cell malignancies
  • most sensitive and reliable immunohistochemical marker for B-cell malignancies and lack of PAX5 expression correlates with the presence of marked plasma cell differentiation
  • master regulator of B-cell development, involved in several leukemia-associated rearrangements, resulting in fusion genes encoding chimeric proteins that antagonize PAX5 transcriptional activity
  • transcription factor required for B-cell development and maintenance
  • B lineage-specific regulator that controls the B lineage-specific gene expression program and immunoglobulin gene V(H) to DJ(H) recombination
  • regulates its target genes by recruiting chromatin-modifying proteins in committed B cells
  • potent transcription factor that plays a key role in B-cell development and cancerous processes
  • controls the identity and development of B cells by repressing lineage-inappropriate genes and activating B-cell-specific genes
  • controls B-cell identity and function by regulating distinct target genes in early and late B lymphopoiesis
  • could positively regulate osteoblastic differentiation, in addition to promoting bone formation and remodeling, as one of the transcription factors essential for controlling osteoblastogenesis independently of RUNX2
  • alternatively spliced transcription factor that regulates B cell development and activation
  • both EBF1 and PAX5 are required for B lineage commitment by repressing distinct and common determinants of alternative cell fates
  • implicated in a new syndrome of susceptibility to pre-B cell neoplasia
  • required for normal B cell development and is frequently mutated or deleted in B cell precursor acute lymphoblastic leukemia (B-ALL)
  • CELLULAR PROCESS nucleotide, transcription
    cell organization/biogenesis
    PHYSIOLOGICAL PROCESS development
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA binding (truncated homeodomain)
    RNA
    small molecule
    protein
  • binding the C terminal domain of importin alpha 1 (KPNA2) by PAX 5 central domain
  • ATP9A is a PAX5 target gene
  • EP300 interacts with the C terminus of PAX5 and acetylates multiple lysine residues within the paired box DNA binding domain of PAX5
  • PAX5 binds to the promoter and enhancer of CD19 gene and remodels chromatin structure at the promoter
  • PAXIP1 is recruited to a PAX5 binding site to promote histone H3 lysine 4 (H3K4) methylation
  • have been implicated in regulating the expression of AICDA (regulates AICDA transcription through its C-terminal-activation domain)
  • is one of the major SOX11 direct targets
  • PAX5 controls MCOLN2 expression
  • PAX5 was found to be an epigenetically inactivated tumour suppressor that inhibits non-small cell lung cancer (NSCLC) proliferation and metastasis, through down-regulating the CTNNB1 pathway and up-regulating GADD45G expression
  • cell & other
    REGULATION
    Other allele specific regulated during B-lymphopoiesis
    DAXX affects PAX5 roles as an activator or a repressor in B cells
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral fusion      
    with IGH in t(9;14)(p13;q32) with diffuse large-cell lymphoma expressing Ki-1 (CD30) antigen, in the related splenic marginal zone lymphoma and in lymphoplasmacytic lymphoma
    tumoral somatic mutation      
    in acute lymphoblastic leukaemia
    tumoral   deletion    
    in acute lymphoblastic leukaemia
    tumoral fusion      
    with ETV6 in t(9;12) (q11;p13) in acute lymphoblastic leukemia
    tumoral fusion      
    fused with the elastin (ELN) by t(7;9)(q11;p13) translocation in B-cell acute lymphoblastic leukemia (B-ALL)
    tumoral   translocation    
    recurrent t(9;15)(p13;q24) in two cases of childhood ALL, with fusion of PAX5 to PML (putative PAX5-PML fusion gene encodes a chimaeric protein that retains the paired domain)
    tumoral fusion      
    with ASXL, in t(9;20)(p11-13;q11) in patients with acute lymphoblastic leukemia
    tumoral fusion      
    with FOXP1 in t(3;9)(p13;p13) recurrent in both childhood and in adult B-ALL
    tumoral fusion      
    PAX5-AUTS2 is a recurrent fusion gene (t(7;9)(q11.2;p13.2)) in pediatric B-cell precursor acute lymphoblastic leukemia
    Susceptibility to B cell leukemia
    Variant & Polymorphism other
  • p.Gly183Ser retains sufficient transcriptional regulatory activity for grossly normal B cell development in the presence of one wild-type copy of PAX5, but it does not have sufficient activity to prevent leukemogenesis after loss of the wild-type PAX5 allele
  • Candidate gene
    Marker most sensitive and reliable immunohistochemical marker for B-cell malignancies
    Therapy target
    SystemTypeDisorderPubmed
    cancerhemopathy 
    possibility that acute lymphoblastic leukemia with PAX5-PML can be treated with arsenic trioxide
    ANIMAL & CELL MODELS